Press Releases July 9, 2026 04:05 PM

Amneal to Report Second Quarter 2026 Results on July 30, 2026

Amneal Pharmaceuticals to announce Q2 2026 financial results on July 30 before market open

By Ajmal Hussain
Share
Twitter Reddit Facebook LinkedIn
AMRX

Amneal Pharmaceuticals, a diversified global biopharmaceutical company, announced that it will report its second quarter 2026 financial results on July 30, 2026, before the market opens. The company will host a live audio webcast for investors and interested parties to discuss the financial results and operational updates.

Amneal to Report Second Quarter 2026 Results on July 30, 2026
AMRX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Amneal Pharmaceuticals focuses on affordable and innovative medicines with a portfolio including complex, specialty, and biosimilar medicines.
  • The company’s segments include Affordable Medicines, Specialty (neurology and endocrinology), and AvKARE distribution to US federal and institutional customers.
  • The Q2 2026 financial results and webcast are scheduled for July 30, providing updates on company performance and strategy.

BRIDGEWATER, N.J., July 09, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced it will report second quarter 2026 financial results on Thursday, July 30, 2026, before market open. The Company will host an audio webcast at 8:30 a.m. ET.

The financial results and live webcast will be available through the Investor Relations section of the Company's website at investors.amneal.com. Individuals may register for the webcast by clicking here. To access the call by phone, dial 1 (833) 461-5787 (U.S.) or view a list of toll-free international numbers here. The access code for is 901153095. A replay of the webcast will be available shortly after the call.

About Amneal
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, New Jersey, is a diversified, global biopharmaceutical leader focused on expanding access to affordable and innovative medicines. Founded in 2002 by brothers and co-CEOs Chirag and Chintu Patel, Amneal was built on the belief that innovation only matters if it’s accessible. Today, Amneal has a diverse and growing portfolio of approximately 300 complex, specialty and biosimilar medicines, delivering over 160 million prescriptions each year, primarily in the United States. Our Affordable Medicines segment spans retail, injectable, and biosimilar products. Our Specialty segment provides branded treatments in neurology, including Parkinson’s disease and migraine, and endocrinology. Our AvKARE segment distributes pharmaceuticals and medical products to U.S. federal, retail, and institutional customers. For more information, visit  and follow us on LinkedIn.

Investor Contact
Anthony DiMeo
VP, Investor Relations
[email protected]


Risks

  • Market performance risk: Financial results may not meet investor expectations, impacting stock price and investor confidence.
  • Regulatory risk: As a biopharmaceutical company, Amneal faces regulatory scrutiny that can impact product approvals and launches.
  • Competitive risk in the pharmaceutical sector due to rapid innovation and pricing pressures impacting revenue and growth potential.

More from Press Releases

Five Star Bancorp Announces Second Quarter 2026 Earnings Release Date and Webcast Jul 9, 2026 Exodus Movement, Inc. June 2026 Treasury Update and Monthly Metrics Jul 9, 2026 Martin Marietta Announces Second-Quarter 2026 Earnings Conference Call Jul 9, 2026 New Era Energy & Digital Announces Final Approval of Settlement Dismissing the State of New Mexico’s Claims Against the Company Jul 9, 2026 Figure Technology Solutions Announces Pricing of Private Offering of $600 Million of Senior Notes Jul 9, 2026